Table 3. Prognostic effect of weight loss and covariates on overall survival (OS), disease-free survival (DFS) and the cumulative incidences of relapse and non-relapse mortality (NRM) (multivariable analysis^*).

	OS		DFS		Relapse		NRM
	HR (95% CI)	P	HR (95% CI)	P	HR† (95% CI)	P	HR† (95% CI)	P
MDS WHO subtype
RA(RS)/RCMD/RAEB1	Ref		Ref		Ref		Ref
RAEB2	0.75 (0.35–1.61)	0.459	0.72 (0.34–1.51)	0.380	0.54 (0.14–2.13)	0.381	0.73 (0.29–1.83)	0.502
Previous treatment
No	Ref		Ref		Ref		Ref
AML-like chemotherapy	0.33 (0.10–1.10)	0.071	0.52 (0.17–1.61)	0.257	4.70 (0.66–33.50)	0.122	0.16 (0.03–0.91)	0.038
HMA/IS	0.75 (0.32–1.78)	0.515	0.88 (0.38–2.03)	0.767	2.21 (0.42–11.82)	0.353	0.67 (0.25–1.80)	0.424
IPSS risk
Intermediate-1	Ref		Ref		Ref		Ref
intermediate-2/high	1.83 (0.79–4.26)	0.160	1.88 (0.84–4.20)	0.125	1.14 (0.25–5.28)	0.864	2.28 (0.84–6.18)	0.107
Donor
UD	Ref		Ref		Ref		Ref
RD	0.24 (0.10–0.60)	0.002	0.39 (0.17–0.87)	0.022	0.87 (0.25–2.95)	0.818	0.19 (0.06–0.66)	0.009
Conditioning
MAC	Ref		Ref		Ref		Ref
RIC	1.33 (0.58–3.04)	0.505	1.43 (0.63–3.24)	0.392	4.37 (0.76–25.29)	0.098	1.25 (0.47–3.31)	0.654
BM blast at alloSCT
≥5%	Ref		Ref		Ref		Ref
<5%	1.30 (0.63–2.68)	0.471	1.03 (0.51–2.10)	0.934	0.79 (0.23–2.70)	0.712	1.02 (0.44–2.37)	0.960
Pre-transplant weight loss
≤2%	Ref		Ref		Ref		Ref
2–5%	2.38 (1.03–5.51)	0.043	2.48 (1.13–5.42)	0.023	3.23 (0.80–13.08)	0.100	2.26 (0.83–6.18)	0.112
>5%	10.05 (3.84–26.30)	<0.001	7.53 (3.06–18.53)	<0.001	14.42 (3.21–64.86)	<0.001	5.96 (1.64–21.58)	0.007

HR: hazard ratio; IS: immunosuppression; MAC: myeloablative conditioning; RD: related donor; RIC: reduced intensity conditioning; UD: unrelated donor.

^*Missing values imputed using “mice” function.

^†Cause-specific HR.